Close Menu
Best in TechnologyBest in Technology
  • News
  • Phones
  • Laptops
  • Gadgets
  • Gaming
  • AI
  • Tips
  • More
    • Web Stories
    • Global
    • Press Release

Subscribe to Updates

Get the latest tech news and updates directly to your inbox.

What's On

Apple’s Big OS Rebrand, OnePlus Embraces AI, and Samsung’s Next Folds—Your Gear News of the Week

31 May 2025

Never Drink Alone: A Guide to Turkish Coffee

31 May 2025

Review: Priority Current Plus Electric Bike

31 May 2025
Facebook X (Twitter) Instagram
Just In
  • Apple’s Big OS Rebrand, OnePlus Embraces AI, and Samsung’s Next Folds—Your Gear News of the Week
  • Never Drink Alone: A Guide to Turkish Coffee
  • Review: Priority Current Plus Electric Bike
  • Review: Staples Union & Scale Electric Standing Desk With Micro Movements
  • Review: Nike x Hyperice Hyperboots
  • Analysts Say Trump Trade Wars Would Harm the Entire US Energy Sector, From Oil to Solar
  • Xiaomi 16 Tipped to Get Snapdragon 8 Elite 2 Chipset, Triple Rear Cameras, More
  • Hell is Us Preview – Show, Don’t Tell
Facebook X (Twitter) Instagram Pinterest Vimeo
Best in TechnologyBest in Technology
  • News
  • Phones
  • Laptops
  • Gadgets
  • Gaming
  • AI
  • Tips
  • More
    • Web Stories
    • Global
    • Press Release
Subscribe
Best in TechnologyBest in Technology
Home » A Key to Detecting Brain Disease Earlier Than Ever
News

A Key to Detecting Brain Disease Earlier Than Ever

News RoomBy News Room15 January 20244 Mins Read
Share Facebook Twitter Pinterest LinkedIn Tumblr Reddit Telegram Email
Share
Facebook Twitter LinkedIn Pinterest Email

Earlier this year, Parkinson’s disease (PD) research entered a new era when the Michael J. Fox Foundation announced a momentous scientific breakthrough—the discovery of a biomarker for PD. It meant that, for the first time ever, we can now pinpoint the earliest known signs of the disease in Parkinson’s patients.

This long-awaited new procedure is called the “alpha-synuclein seeding amplification assay” (SAA), and it’s capable of detecting the misfolded alpha-synuclein in spinal fluid—the wayward protein clearly linked to Parkinson’s. It separates, with a stunning 90 percent specificity, those who have evidence of PD pathology in their cells from those who do not. It does so even before the emergence of symptoms, much like the way high blood pressure or cholesterol levels are used to detect cardiovascular risk long before a heart attack lands someone in the ER.

It would be hard to overstate the implications of this development for people living with dysfunction in their alpha-synuclein. For one thing, we’ve never had a way to know who these people are—that is, until the moment of diagnosis, by which point ongoing damage to brain cells is already well underway. As for the diagnosis itself, which for most people comes as a bolt from the blue, it has always been frustratingly subjective and essentially based on a physician’s opinion following a brief once-over in the doctor’s office—not very useful for medical care provision, let alone biomedical drug development.

The new SAA test is already being integrated into drug trials as the first measure that can objectively identify people with the biology we’re targeting—offering drugmakers increased assurance that they are testing experimental treatments in the right populations. For biopharma firms weighing a decision to enter or stay in the high-risk neurological disease space, this changes the value proposition of investment on its face. In 2024, we will see a ramp-up of potential new drugs entering the pipeline and progressing along their path toward pharmacy shelves.

What’s just as remarkable is how the SAA breakthrough was arrived at. The search for the biomarker required finding and studying “needles in a haystack”: people without any traditional symptoms of PD and unwittingly living with increased risk for the disease. It was critical to figure out what biology set them apart from those who don’t get Parkinson’s. But how do you find someone who doesn’t know they’re being looked for?

As it turns out, your sense of smell is a surprisingly good predictor of brain disease. (We’re talking here not about the short-term smell loss associated with Covid-19, but significant and enduring smell loss that persists over years.) For a while now, researchers have known about the link between smell loss and neurodegeneration, especially in the presence of certain other risk factors, such as a diagnosis with REM behavior disorder (RBD), a sleep disorder. Research shows that half of those over age 60 are living with some degree of smell loss, yet the majority don’t realize it until they’re tested. If you couple this with the fact that all major brain diseases—Alzheimer’s, Parkinson’s, ALS, Huntington’s—are associated with some amount of smell loss, this is astounding.

The Michael J. Fox Foundation’s large-scale observational study of Parkinson’s set out to use poor smell as one of its criteria for finding and enrolling at-risk individuals. (We should note that, for this risk group, it’s still unclear if or when the disease may eventually show up.) The highly sophisticated screening device used? A humble scratch-and-sniff test, albeit the scientifically validated variety.

Until the SAA biomarker was validated, a reduced sense of smell couldn’t be objectively linked to the presence of underlying Parkinson’s disease biology. But now we can report that the test accurately diagnosed disease in 99 percent of people with poor smell and so-called sporadic Parkinson’s (in other words, those with no genetic mutation).

In 2024, we will begin to see a sea change in the possibilities around screening for and predicting PD and, very possibly, other diseases of aging. An annual scratch-and-sniff test may soon become as commonplace as your mammogram or colonoscopy. In 2024, with widespread adoption, this simple, cheap, and accessible mechanism will radically alter the landscape of what’s possible in Parkinson’s research and care.

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Previous ArticleVoltas 1.5 Ton 3 Star Inverter Window AC (183V Vertis Elite Marvel 4011484) at Lowest Price in India (15th January 2024)
Next Article Buccaneers vs Eagles live stream: Can you watch for free?

Related Articles

News

Apple’s Big OS Rebrand, OnePlus Embraces AI, and Samsung’s Next Folds—Your Gear News of the Week

31 May 2025
News

Never Drink Alone: A Guide to Turkish Coffee

31 May 2025
News

Review: Priority Current Plus Electric Bike

31 May 2025
News

Review: Staples Union & Scale Electric Standing Desk With Micro Movements

31 May 2025
News

Review: Nike x Hyperice Hyperboots

31 May 2025
News

Analysts Say Trump Trade Wars Would Harm the Entire US Energy Sector, From Oil to Solar

31 May 2025
Demo
Top Articles

Costco partners with Electric Era to bring back EV charging in the U.S.

28 October 202495 Views

ChatGPT o1 vs. o1-mini vs. 4o: Which should you use?

15 December 202490 Views

5 laptops to buy instead of the M4 MacBook Pro

17 November 202466 Views

Subscribe to Updates

Get the latest tech news and updates directly to your inbox.

Latest News
News

Analysts Say Trump Trade Wars Would Harm the Entire US Energy Sector, From Oil to Solar

News Room31 May 2025
Phones

Xiaomi 16 Tipped to Get Snapdragon 8 Elite 2 Chipset, Triple Rear Cameras, More

News Room31 May 2025
Gaming

Hell is Us Preview – Show, Don’t Tell

News Room31 May 2025
Most Popular

The Spectacular Burnout of a Solar Panel Salesman

13 January 2025122 Views

Costco partners with Electric Era to bring back EV charging in the U.S.

28 October 202495 Views

ChatGPT o1 vs. o1-mini vs. 4o: Which should you use?

15 December 202490 Views
Our Picks

Review: Staples Union & Scale Electric Standing Desk With Micro Movements

31 May 2025

Review: Nike x Hyperice Hyperboots

31 May 2025

Analysts Say Trump Trade Wars Would Harm the Entire US Energy Sector, From Oil to Solar

31 May 2025

Subscribe to Updates

Get the latest tech news and updates directly to your inbox.

Facebook X (Twitter) Instagram Pinterest
  • Privacy Policy
  • Terms of use
  • Advertise
  • Contact Us
© 2025 Best in Technology. All Rights Reserved.

Type above and press Enter to search. Press Esc to cancel.